Island Pharma Will Host Webinar on FDA Feedback for Antiviral
Island Pharmaceuticals has announced an upcoming webinar to review the FDA’s recent feedback on the development and approval pathway for Galidesivir, including its potential eligibility for a Priority Review Voucher and details on forthcoming clinical initiatives. This update underscores the company’s continued progress in advancing Galidesivir, a broad-spectrum antiviral with the potential to address critical unmet medical needs and strengthen Island Pharmaceuticals’ position within the antiviral therapeutics market.
Island Pharma Will Host Webinar on FDA Feedback for Antiviral